TINLY - Teijin Limited

Other OTC - Other OTC Delayed Price. Currency in USD
0.00 (0.00%)
At close: 3:33PM EST
Stock chart is not supported by your current browser
Previous Close19.55
Bid0.00 x 0
Ask0.00 x 0
Day's Range19.55 - 19.55
52 Week Range15.10 - 20.48
Avg. Volume261
Market Cap3.788B
Beta (3Y Monthly)N/A
PE Ratio (TTM)9.27
EPS (TTM)2.11
Earnings DateN/A
Forward Dividend & Yield0.73 (3.73%)
Ex-Dividend Date2019-03-28
1y Target EstN/A
  • Teijin and NeuroSigma Enter into Exclusive License Agreement
    PR Newswire

    Teijin and NeuroSigma Enter into Exclusive License Agreement

    LOS ANGELES, Oct. 17, 2019 /PRNewswire/ -- Teijin Limited (Teijin) and NeuroSigma, Inc. (NeuroSigma), a Los Angeles-based bioelectronics company focused on developing Trigeminal Nerve Stimulation (TNS) technology for the treatment of neuropsychiatric and neurological indications, today announced entering into a partnership based on an exclusive license agreement that grants Teijin Pharma, the core company of Teijin's healthcare business, exclusive rights: (i) to NeuroSigma's TNS patent rights in Japan related to attention deficit hyperactivity disorder (ADHD) and (ii) to market the Monarch eTNS System® for the non-invasive treatment of ADHD in Japan. As part of the agreement, Teijin Pharma will seek regulatory approval in Japan for the Monarch eTNS System (Monarch) for the treatment of ADHD.

  • We're sorry this is all we were able to find about this topic.